ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid

• ClinicalTrials.gov Identifier: NCT00339131
• Recruitment Status: Completed
• First Posted: June 20, 2006
• Last Update Posted: October 12, 2011
• Sponsor: Molecular Insight Pharmaceuticals, Inc.
• Information provided by (Responsible Party): Molecular Insight Pharmaceuticals, Inc.

Study Description

Brief Summary:

The purpose of this study is to test the safety of a drug called Ultratrace iobenguane I 131 that has radioactivity, to measure how long it takes for the drug to be absorbed and passed out of the body, and to measure how much radioactivity is absorbed into different tissues of the body.

Condition or disease	Intervention/treatment	Phase
Pheochromocytoma; Paraganglioma; Carcinoid	Drug: Ultratrace iobenguane I 131	Phase 1

Detailed Description:

Iobenguane, which is also known as MIBG, has been used in many patients who have types of cancers caused by what are known as neuroendocrine tumors, such as pheochromocytoma, paraganglioma, and carcinoid. Iobenguane is absorbed by neuroendocrine tumor cells. The radioactive portion of the study drug, Ultratrace iobenguane, is a form of iodine called I 131. The I 131 is absorbed into the tumor with the iobenguane, and the radioactivity should kill the tumors. The type of iobenguane being studied is called Ultratrace because of the new way in which this form of iobenguane is made. This study is the first time in which Ultratrace iobenguane will be given to patients. The purpose of the study is to give a low dose of iobenguane just to find out if the drug is safe, to measure how long it takes the drug to be absorbed and passed out of the body, and to see how much radioactivity is absorbed by different types of tissues of the body.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 24 participants
• Allocation: Non-Randomized
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Diagnostic
• Official Title: Phase 1 Study Evaluating the Safety, Distribution, Metabolism, and Radiation Dosimetry of ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma or Metastatic Carcinoid
• Study Start Date: June 2006
• Actual Study Completion Date: January 2007

Arms and Interventions

Outcome Measures

Primary Outcome Measures :

1. whole body imaging immediately post-dose
2. whole body imaging 1 hour post-dose
3. whole body imaging 3 hours post-dose
4. whole body imaging 6 hours post-dose
5. whole body imaging 24 hours post-dose
6. whole body imaging 48 hours post-dose
7. whole body imaging 120 hours post-dose

Secondary Outcome Measures :

1. blood and urine samples pre-dose
2. blood and urine samples immediately post-dose
3. blood and urine samples 1 hour post-dose
4. blood and urine samples 3 hours post-dose
5. blood and urine samples 6 hours post-dose
6. blood and urine samples 24 hours post-dose
7. blood and urine samples 48 hours post-dose
8. blood and urine samples 120 hours post-dose
9. continuous urine samples at intervals of 0-6 hours, 6-24 hours, 24-48 hours, 48-72 hours, 72-96 hours and 96-120 hours post-dose
10. monitoring for adverse events starting when the patient consents to be in the study until 2 weeks post-dose

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

Patients will enter one of two study arms depending on their type of neuroendocrine tumor.

Arm P patients must:

• Have a biochemical or histopathological diagnosis of either adrenal pheochromocytoma or extra-adrenal paraganglioma (biochemical diagnosis includes plasma-free metanephrines and 24-hour urine test for catecholamines/metanephrines)
• Disease is metastatic or has recurred following surgery
• Have a CT scan performed (for later measurement of disease volume by the core lab) within 90 days of the administration of study drug without any interventions between CT and iobenguane I 131 imaging.

Arm C patients must:

• Have a histopathological diagnosis of carcinoid, or by plasma chromogranin A (CgA) and 24-hour urine test for 5-hydroxyindole-acetic-acid (5HIAA)
• Disease is metastatic or has recurred following surgery
• Have a CT scan performed (for the later measurement of disease volume by the core lab) within 90 days of the administration of study drug without any interventions between CT and iobenguane I 131 imaging.

All patients in Arm P and Arm C must also meet each of the following inclusion criteria:

• Provide written informed consent and are willing to comply with protocol requirements
• Are at least 18 years of age
• If female, then not of childbearing potential as documented by history (e.g., tubal ligation or hysterectomy) or is post menopausal with a minimum 1 year without menses
• If female of childbearing potential, has a negative serum HCG pregnancy test within 24 hours prior to receiving iobenguane I 131
• If female of childbearing potential, agrees to use an acceptable form of birth control, defined as abstinence or use of IUD, oral contraceptive, barrier and spermicide, or hormonal implant, throughout the study period

Exclusion Criteria:

• • Females who are nursing

  • Documented history of significant allergy that required medical intervention to shellfish, X-ray contrast media , iodine/iodides, or iobenguane
  • Administered a radioisotope within 5 effective half-lives of that radioisotope prior to study enrollment
  • Karnofsky performance status is < 60
  • Serum creatinine > 2.0 mg/dL
  • Total bilirubin > 1.5 times the upper limit of normal
  • AST/SGOT or ALT/SGPT > 3 times the upper limit of normal
  • Has received an investigational compound and/or medical device within 30 days before admission into this study
  • Has any medical condition or other circumstances which would significantly decrease the chances of obtaining reliable data, achieving study objectives, or completing the study and/or post dose follow-up examinations
  • Is determined by the Investigator that the patient is clinically unsuitable for the study
  • Has received a medication which inhibits uptake of iobenguane I 131 within 2 weeks prior to the administration of study drug. Patients must not have taken tricyclic antidepressants or related drugs within 6 weeks prior to enrollment.

Contacts and Locations

Sponsors and Collaborators

Molecular Insight Pharmaceuticals, Inc.

Investigators

• Principal Investigator: Ralph E Coleman, MD; Duke University

More Information

• Responsible Party: Molecular Insight Pharmaceuticals, Inc.
• ClinicalTrials.gov Identifier: NCT00339131
• Other Study ID Numbers: MIP-IB11
• First Posted: June 20, 2006
• Last Update Posted: October 12, 2011
• Last Verified: October 2011

Keywords provided by Molecular Insight Pharmaceuticals, Inc.:

radiopharmaceutical; radiation dosimetry; iodine; MIBG; iobenguane; Ultratrace; neuroendocrine tumors

Additional relevant MeSH terms:

Carcinoid Tumor; Pheochromocytoma; Paraganglioma; Carotid Body Tumor; Neuroendocrine Tumors; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue; Paraganglioma, Extra-Adrenal; 3-Iodobenzylguanidine; Antineoplastic Agents; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action; Radiopharmaceuticals